Halogenated Arylboronic Acid Emulsion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polymer emulsions used in medical technologies are inherently unstable, leading to destabilization phenomena such as coalescence, flocculation, and creaming, which can result in phase separation and affect the formation of coatings and microparticles, particularly when used for implantable or injectable medical applications, where biocompatibility and stability are critical.
Innovation Solution
Incorporating halogenated arylboronic acids, such as chlorophenylboronic acid, into the emulsion compositions to enhance stability, allowing for the formation of stable polymeric matrices and improved biocompatibility, with reactive chemistries like silane-ether groups facilitating crosslinking and polymer reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymer emulsions are used for medical applications, then the emulsion can be applied to form coatings and microparticles, but the emulsion is inherently unstable and undergoes coalescence, flocculation, and creaming leading to phase separation
Solution Approach 1:
The patent introduces arylboronic acids as intermediary substances that mediate between the hydrophobic polymer and the aqueous environment. The arylboronic acid stabilizes the emulsion by forming a protective interface layer around hydrophobic polymer particles, preventing coalescence, flocculation, and creaming. This intermediary substance enables the emulsion to maintain stable composition over time while remaining applicable for forming coatings and microparticles in medical devices.
2Reliability
If surfactants are added to stabilize emulsions, then some stabilization is achieved, but the surfactants may not be particularly effective or may not stabilize the emulsion for a desired period of time, and may not be biocompatible
Solution Approach 1:
The patent changes the chemical parameters of the emulsion system by incorporating arylboronic acids with specific molecular structures and properties. The arylboronic acid modifies the interfacial properties and stabilizes the emulsion through unique chemical interactions that provide long-term stability. This parameter change enables the emulsion to maintain stability throughout its shelf life and for the desired duration in medical applications, overcoming the limitations of conventional surfactants.
3Manufacturing precision
If emulsion destabilization occurs, then phase separation is caused, but this affects the formation of coatings and microparticles and may affect bioactive agents
Solution Approach 1:
The patent applies beforehand cushioning by incorporating arylboronic acids into the emulsion formulation in advance, before any destabilization can occur. The arylboronic acid pre-establishes a protective stabilization mechanism that cushions against coalescence, flocculation, and creaming. This preventive approach ensures that phase separation is avoided throughout the entire process of coating and microparticle formation, maintaining manufacturing precision and protecting bioactive agents from degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of halogenated arylboronic acids in polymer emulsions provides exceptional stability, extending shelf life, ensuring uniformity and quality of formed articles, and enhancing the stability of drug-containing implantable or injectable articles, allowing for controlled release of bioactive agents.
Implementation Method 1
Incorporating halogenated arylboronic acids, such as chlorophenylboronic acid, into the emulsion compositions to enhance stability
Implementation Method 2
with reactive chemistries like silane-ether groups facilitating crosslinking and polymer reactions
Implementation Method 3
provides exceptional stability, extending shelf life, ensuring uniformity and quality of formed articles
Data Source
AI summary
The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.